The USA's CEL-SCI has granted Byron Biopharma exclusive rights to market the potential blockbuster cancer drug Multikine in South Africa, in return for a $125,000 upfront payment and a $750,000 investment in CEL-SCI stock. The local firm will be responsible for the registration and sales, while CEL-SCI will manufacture the product. Revenues will be divided evenly between the two companies.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze